Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | OTUD7B | Q6GQQ9 | 2/20 | 0.40 |
| ▸ | CHUK | O15111 | 2/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | INSR | P06213 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3075841 | 0.88 | IKBKB (0.49) | IKBKBCHEK1AKT2ACVR1FTO | |
| SCHEMBL22704005 | 0.83 | AR (0.39) | IKBKBCHEK1AKT2CYP11B2AR | |
| SCHEMBL3080716 | 0.82 | CYP11B1 (0.50) | CHEK1AKT2CYP11B2ACVR1CYP11B1 | |
| SCHEMBL30545918 | 0.80 | AR (0.37) | IKBKBCHEK1AKT2ARNSD2 | |
| SCHEMBL22524443 | 0.80 | AR (0.37) | IKBKBCHEK1AKT2ARNSD2 | |
| SCHEMBL3083270 | 0.80 | KDM4E (0.51) | CHEK1AKT2ARACVR1ROCK2 | |
| SCHEMBL24186806 | 0.79 | CYP11B2 (0.44) | IKBKBCYP11B2ARTRPV4CYP11B1 | |
| SCHEMBL3075671 | 0.79 | AR (0.57) | CHEK1AKT2ARNSD2 | |
| SCHEMBL22524466 | 0.75 | AR (0.34) | CHEK1AKT2ARNSD2FASN | |
| SCHEMBL3074271 | 0.74 | CHEK1 (0.59) | IKBKBCHEK1AKT2ACVR1OTUD7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101842357-A | Substituted pyrazole derivatives | TAKEDA PHARMACEUTICAL | 2010-09-22 | — | — | CN | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | IKBKB 2703/4885CHEK1 1685/4885AKT2 1615/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | IKBKB 2688/4885CHEK1 1722/4885AKT2 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.